Evotec acquires remaining 30% of Indian Joint Venture from DIL

Thursday, 29. September 2011 07:23
Evotec AG /
Evotec acquires remaining 30% of Indian Joint Venture from DIL
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.

Hamburg, Germany -29 September 2011: Evotec AG (Frankfurt Stock Exchange: EVT,
TecDAX) today announced that it has signed a Share Purchase Agreement to acquire
the remaining 30% of equity of its Joint Venture with DIL Limited, India for

The acquisition of DIL's 30% outstanding equity in the joint venture will give
Evotec 100% ownership of this subsidiary. Evotec acquired 70% of the equity of
Research Support International Private Limited (RSIPL), in August 2009 which was
subsequently renamed Evotec (India) Private Limited.  The transaction is
anticipated to close on 4(th) October.

With its now 100% owned Indian subsidiary Evotec has successfully expanded its
global scientific resource to offer the most complete and cost efficient drug
discovery solutions to the pharmaceutical and biotech industry. Operating out of
Thane, Mumbai, Evotec India has 140 scientists, focusing primarily on Medicinal
Chemistry. Going forward the intention is to further grow and expand this

Colin Bond, Chief Financial Officer of Evotec stated: "With the purchase of the
remaining 30% of our successful Indian Joint Venture, Evotec is now able to
operate and accelerate this business with full control. This transaction will
allow financial optimization and a significant reduction in administration. The
deal also gives Evotec complete freedom to expand its activity in India in
future without any restrictions. The access to a global best quality talent pool
is the strategic reason for Evotec to establish operations in India. We would
like to thank our friends at DIL for supporting us over the last two years and
wish them well as they pursue new business avenues".

Despite the fact that Evotec pays in cash, the company keeps it cash guidance of
more than €60 Mio by year end.

Contact Evotec AG:

Dr Werner Lanthaler
Chief Executive Officer
Phone: +49.(0)40.56081-242

Forward-Looking Statements - Information set forth in this press release
contains forward-looking statements, which involve a number of risks and
uncertainties. The forward-looking statements contained herein represent the
judgement of Evotec as of the date of this report. Such forward-looking
statements are neither promises nor guarantees, but are subject to a variety of
risks and uncertainties, many of which are beyond our control, and which could
cause actual results to differ materially from those contemplated in these
forward-looking statements. We expressly disclaim any obligation or undertaking
to release publicly any updates or revisions to any such statements to reflect
any change in our expectations or any change in events, conditions or
circumstances on which any such statement is based.

--- End of Message ---

Evotec AG
Schnackenburgallee 114 Hamburg Germany

WKN: 566480;ISIN: DE0005664809;
Listed: Freiverkehr in Börse Stuttgart,
Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg,
Freiverkehr in Börse Berlin,
Freiverkehr in Börse Düsseldorf,
Freiverkehr in Bayerische Börse München,
Freiverkehr in Niedersächsische Börse zu Hannover,
Prime Standard in Frankfurter Wertpapierbörse,
Regulierter Markt in Frankfurter Wertpapierbörse;

PDF of Press Release:

This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.

Source: Evotec AG via Thomson Reuters ONE

Related Links: Evotec SE
Copyright GlobeNewswire, Inc. 2016. All rights reserved.
You can register yourself on the website to receive press releases directly via e-mail to your own e-mail account.